CoLucid Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
08 Noviembre 2016 - 7:00AM
CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical
company that is developing lasmiditan oral tablets for the acute
treatment of migraine in adults, with or without aura, announced
today it will provide a corporate overview at the Stifel 2016
Healthcare Conference, being held on November 15-16 in New York
City.
Stifel 2016 Healthcare Conference |
Date: |
|
Tuesday, November
15 |
Time: |
|
2:15pm Eastern
Time |
Location: |
|
The Lotte New York
Palace Hotel, Holmes I Room |
Webcast: |
|
http://wsw.com/webcast/stifel5/clcd |
About CoLucid Pharmaceuticals, Inc.CoLucid is
developing lasmiditan oral tablets for the acute treatment of
migraine headaches in adults and intravenous lasmiditan for the
acute treatment of headache pain associated with migraine in adults
in emergency room and other urgent care settings.
CONTACT
Thomas Mathers
Chief Executive Officer
CoLucid Pharmaceuticals, Inc.
(857) 285-6494
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Colucid Pharmaceuticals, Inc. (NASDAQ): 0 recent articles
Más de Artículos de Noticias